Biotechnology is increasingly about crunching the numbers. Thankfully, the crunching is being performed by computational platforms, including artificial intelligence platforms, whether they are generating single-cell analyses, sifting through biomarker data, suggesting physicochemical tweaks to drug candidates, finding new uses for old drugs, or optimizing drug manufacturing processes. All of these applications are covered in the April issue of GEN, which emphasizes that in every instance, computational resources, however sophisticated, cannot accomplish much on their own. Still, as this issue of GEN suggests, there is enormous potential in combining the complementary strengths of computers and humans.